Simnotrelvir + ritonavir - Simcere Pharmaceutical Group
Alternative Names: Anti-COVID 19 oral 3CL inhibitor; Anti-COVID-19 3CL inhibitor; SD-8432; SIM-0417; Simnotrelvir; Simnotrelvir/ritonavir tablets (co-packaged); SSD-8432; XIANNUOXINLatest Information Update: 27 Apr 2023
At a glance
- Originator Shanghai Institute of Materia Medica
- Developer Simcere Pharmaceutical Group
- Class Amides; Antivirals; Carbamates; Small molecules; Thiazoles
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections
Most Recent Events
- 27 Apr 2023 Simcere Pharmaceutical initiates a phase I pharmacokinetic trial (In volunteers, In the elderly) in China (PO) (NCT05826249)
- 21 Mar 2023 Jiangsu Simcere Pharmaceutical completes a phase II/III trial for Covid-2019 infections in China (PO) (NCT05506176)
- 26 Feb 2023 Launched for COVID-2019 infections in China (PO)